| Filed On | Filing |
|---|---|
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026 |
| 05 Oct 2026 |
Form 4: Ferrante Karen Jean, Director
Granted 759 Stock Option (Right to Buy) |
| 02 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 1, 2026, Cogent Biosciences, Inc. (the “Company”) entered into a Commercial Supply Agreement (the “Agreement”) with Hovione FarmaCiencia S.A. (“Hovione”) to manufacture bezuclastinib spray-dried dispersion and bezuclastinib ... |
| 31 Aug 2026 |
Form 4: Morris Arlene, Director
Received 45,510 shares by exercise or conversion ($245K) · Sold 45,510 shares ($1.69M) |
| 27 Aug 2026 | 144 |
| 13 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 |
8-K: Other Events
We have examined the Registration Statement on Form S-3 (the “Registration Statement”) of Cogent Biosciences, Inc., a Delaware corporation (the “Company”), filed with the Securities and Exchange Commission (the “Commission”) pursuant to ... |
| 10 Aug 2026 | 424B5 |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30 |
| 31 Jul 2026 | SCHEDULE 13G |
| 27 Jul 2026 | SCHEDULE 13G/A |
| 06 Jul 2026 |
Form 4: Ferrante Karen Jean, Director
Granted 627 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Harwin Peter Evan, Director
Granted 17,901 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Ferrante Karen Jean, Director
Granted 17,901 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Cain Christopher W., Director
Granted 17,901 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Shegog Todd, Director
Granted 17,901 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Morris Arlene, Director
Granted 17,901 Stock Option (Right to Buy) |
| 11 Jun 2026 |
Form 4: Ros Matthew, Director
Granted 17,901 Stock Option (Right to Buy) |
Loading...